期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

原发性血小板增多症用羟基脲治疗后出现骨髓增生异常综合征伴原位溶血1例 被引量：1

Myelodysplastic syndrome with hemolysis in situ after treatment of essential thrombocythemia with hydroxyurea:a case report and literature review
原文传递
导出
摘要 原发性血小板增多症（essential thrombocythemia,ET）是一种造血系统疾病,临床表现为血小板增多,ET患者血栓形成、进展为骨髓纤维化和转变为急性白血病、骨髓增生异常综合征（MDS）的危险性增加。目前,国内外有关ET转化为急性白血病的报道较多,转化为MDS伴原位溶血的报道较少,本文将我院收治的1例病例报告如下,并结合有关文献进行讨论。 Summary One patient with essential thrombocythemia after treatment with hydroxyurea were reported and related literature were reviewed. Patients with essential thrombocythemia have a propensity to develop myelodys- plastic syndrome （MDS） and acute myeloid leukemia （AML） after treatment with hydroxyurea.
作者 吴圣豪 赵成敏 陈松燕 郑翠苹
机构地区 温州市中心医院血液化疗科
出处 《临床血液学杂志》 CAS 2015年第3期436-437,共2页 Journal of Clinical Hematology
关键词 原发性血小板增多症 羟基脲 骨髓增生异常综合征 原位溶血 essential thrombocythemia hydroxyurea myelodysplastic syndrome hemolysis in situ
分类号 R558 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献7

  • 1Chim CS,Kwong YI.,Lie AK,et al. Long-term out- come of 231 patients with essential thrombocythemia= prognostic factors for thrombosis, bleeding, myelofi- brosis,and leukemia[J]. Arch Intern Med, 2005,165 : 2651 -2658.
  • 2Passamonti F, Rumi E, Arcaini L, et al. Prognostic fac- tors for thrombosis, myelofibrosis,and leukemia in es sential thrombocythemia:a study of 605 patients[J]. Haematologica, 2008,93 : 1645 - 1651.
  • 3Palandri F, Catani I., Testoni N, et al. I.ong term fol- low-up of 386 consecutive patients with essential thromhocythemia:safety of cytoreductive therapy[J]. Am J Hematol,2009,84:215-220.
  • 4Nielsen I, Hasselbalch HC. Acute leukemia and myelo- dysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan[J]. Am J Hematol, 2003,74 : 26 - 31.
  • 5Bj/Srkholm M,I)erolf AR, Hultcrantz M, et al. Treat- ment related risk factors for transformation to. acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms[J]. J Clin Oneol, 2012, 29:2410-2415.
  • 6Tefferi A. Classification,diagnosis and management of myeloproliferative disorders in the JAK2V617F era [-J~. Hematology Am Soc Hematol Educ Program, 2006,36:240-245.
  • 7Ding Y, Harada Y,Imagawa J,et al. AML1/RUNX1 point mutation possibly promotes leukemic transfor- mation in myeloproliferative neoplasms [J]. Blood, 2009,114:5201-5205.

同被引文献9

引证文献1

临床血液学杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部